Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

Dow:

Nasdaq:

S&P 500:

AMGN

$466.011.15%5.28

시간 외 거래: 466.67+0.66 +0.14%

Amgen Inc (AMGN)

Date: O: H: L: C: Vol:

Amgen Inc 주식(AMGN)의 최신 뉴스

AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth - Zacks Investment Research

Obstructive Sleep Apnea Clinical Trial and Competitive Landscape Expands as 18+ Leading Companies Accelerate Drug Development | DelveInsight - GlobeNewswire Inc.

Should You Invest in the iShares Biotechnology ETF (IBB)? - Zacks Investment Research

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy? - Zacks Investment Research

FDA warns Amgen over cancer drug promotional video - TradingView

Amgen Announces the Appointment of David Gibbs to Its Board of Directors - Oncodaily

Amgen (AMGN) Maintains Quarterly Dividend at $2.52 with 2.25% Yi - GuruFocus

AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND - Amgen

Regeneron, Amgen Further Narrow Lawsuit Over Eylea Biosimilars - Bloomberg Law News

FDA Flags Amgen's Vectibix Promotional Video as Misleading, Rais - GuruFocus

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 - Amgen

Beyond the DNA We Inherit: A Broader View of Human Genetics - Amgen

Amgen receives FDA warning letter over Vectibix ad - Seeking Alpha

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - Yahoo Finance

Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue - The Motley Fool

FDA warns Amgen over cancer drug promotional video - Reuters

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? - The Motley Fool

Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool

Amgen Stock: A Biotech Bargain Heading Into Q3 Earnings (NASDAQ:AMGN) - Seeking Alpha

AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS - Amgen

FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow

ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data - BioPharma Dive

FDA Approval for PAVBLU issued to AMGEN INC - Quantisnow

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? - The Motley Fool

Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer - Benzinga

Amgen's cancer drug combo cut death risk by 58% in lung cancer trial - Quartz

Is AMGN Overvalued? DCF Says Worth $204 - GuruFocus

Breakfast News: Science Strikes Back at Cancer - The Motley Fool

Amgen Inc. $AMGN Stock Position Raised by Sigma Planning Corp - MarketBeat

2,418 Shares of Amgen Inc. $AMGN Bought by IRON Financial LLC - MarketBeat

Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study - Bloomberg.com

Oppenheimer reiterates Amgen stock rating on cancer drug data - Investing.com

Amgen Inc (Derivatives) Price History and Historical Data - CoinMarketCap

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? - The Motley Fool

Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - The Motley Fool

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow - Seeking Alpha

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER - Amgen

Amgen, Astra Drug Duo Boosts Survival for Deadly Lung Cancer - Bloomberg.com

Here's Why Amgen (AMGN) Fell More Than Broader Market - Zacks Investment Research

Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch

Innovation Lives Here: 25 Years of Amgen in Cambridge - Amgen

Amgen Inc. Estimates – NASDAQ:AMGN - TradingView

Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research

Amgen Inc Stock Futures,Dec-202 (SAMGN=F) interactive stock chart - Yahoo Finance UK

Amgen Inc Stock Futures,Dec-202 (SAMGN=F) latest stock news and headlines - Yahoo Finance UK

Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? - The Motley Fool

AMGN와(과) 유사한 종목

AZN$186.657.02%

GILD$170.683.06%

NVS$160.790.19%

MRK$149.522.18%